552331-16-5

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-METHYL-1H-INDAZOLE is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity. It contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-BROMO-3-METHYL-1H-INDAZOLE serves as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation enhances the effectiveness of these products in controlling pests and weeds.
Used in Antiviral and Antibacterial Applications:
5-BROMO-3-METHYL-1H-INDAZOLE has been studied for its potential biological activities, including its role as an antiviral and antibacterial agent. Its unique chemical properties allow it to target and inhibit the replication of viruses and bacteria, making it a promising candidate for the development of new antiviral and antibacterial treatments.
Used in Materials Science:
5-BROMO-3-METHYL-1H-INDAZOLE has been investigated for its use in materials science due to its unique chemical structure. Its properties can be harnessed to develop new materials with specific characteristics, such as improved stability, reactivity, or conductivity.
Used in Organic Synthesis:
In the field of organic synthesis, 5-BROMO-3-METHYL-1H-INDAZOLE is utilized as a versatile intermediate for the synthesis of various organic compounds. Its reactivity and structural features enable the formation of a wide range of products with diverse applications in various industries.

InChI:InChI=1/C8H7BrN2/c1-5-7-4-6(9)2-3-8(7)11-10-5/h2-4H,1H3,(H,10,11)

Upstream product

• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 552331-15-4 1-(5-bromo-2-fluorophenyl)ethan-1-ol 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 45762-41-2 4-bromo-2-ethylaniline 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 41877-24-1 1-(5-bromo-2-nitrophenyl)ethane-1-one 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 

Downstream Products

• 903875-31-0 5-bromo-1-(4-methoxybenzyl)-3-methyl-1H-indazole 
• 903875-32-1 5-bromo-2-(4-methoxybenzyl)-3-methyl-2H-indazole 
• 885223-58-5 3-methyl-1H-indazole-5-carboxylic acid 
• 1015068-76-4 3-methyl-1H-indazole-5-carboxylic acid methyl ester 
• 942578-51-0 1-benzyloxymethyl-5-bromo-3-methyl-indazole 
• 1312705-18-2 1-[4-chloro-2-(trifluoromethyl)-benzyl]-3-methyl-1H-indazol-5-carbaldehyde 
• 878064-16-5 5-bromo-2,3-dimethyl-2H-indazole 
• 552331-30-3 5-bromo-1,3-dimethyl-1H-indazole 
• 864771-17-5 3-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole 
• 904324-81-8 {1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-4-phenyl-butyl}-carbamic acid tert-butyl ester 
• 904324-80-7 {1-benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butyl}-carbamic acid tert-butyl ester 
• 904324-79-4 {1-benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

A 1H-indazole derivatives preparation method

The invention provides a method for preparing 3-methyl-5-R-1H-indazole easily, safely and efficiently without performing any hydrazine hydrate reflux heating reaction or purifying a product and making the product pass through a column. The method at least comprises the following steps of: a, performing a diazo-reaction on 2-amino-5-R-hypnone serving as a raw material or an intermediate under the condition of an acid solution to generate a diazo salt; b, slowly adding a stannous chloride-hydrate hydrochloric acid solution into the diazo salt obtained in the step a for reacting to generate a 3-methyl-5-R-1H-indazole solution; and c, cooling the solution obtained in the step b under the condition that the pH value is 8-9, and precipitating a product out, wherein R in the steps above represents H or a halogen element.

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

PYRIDOPYRAZINES AS ANTICANCER AGENTS

The present invention relates to pyridopyrazine derivatives and solvates, hydrates and pharmaceutically acceptable salts thereof, the use of them in the prevention and/or the treatment of cancer diseases, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the prevention and/or treatment of cancer diseases.˙

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.

2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40.